This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read PTC Therapeutics’s 8K filing here.
About PTC Therapeutics
PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
See Also
- Five stocks we like better than PTC Therapeutics
- What Are Dividends? Buy the Best Dividend Stocks
- Semtech Stock Leads Industrial Semiconductors’ Comeback
- How to Most Effectively Use the MarketBeat Earnings Screener
- Dogs of Tech: 3 Semiconductor Stocks Set for a 2025 Rebound
- How to Calculate Inflation Rate
- 2 Home Improvement Leaders Building Momentum for Upside
